JPRN-UMIN000029988Not yet recruitingPhase 2
Effect and safety on carteorol for infantile hemangioma - Effect and safety on carteorol for infantile hemangioma
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Takatsuki General Hospital
- Enrollment
- 30
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 35days-old to 150days-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 congenital hemangioma, Kasabah-Merritt syndrome 2 hypoglycemia, hypotension, bradycardia (arrhythmia), cardiac function disorder 3 Otehr drug administaraion interacted with carteorol within 14 days 4 history of other therapy foy infantile hemangioma(steroid therapy, laser therapy etc)
Investigators
Similar Trials
Completed
Not Applicable
Efficacy of proplanorol for infantile hemangiomaInfantile HemangiomaJPRN-UMIN000020220Tohoku University Hospital25
Withdrawn
Phase 2
The Use of Ketorolac in Surgical NeonatesPostoperative Pain Control in Surgical NeonatesNCT01667120Nationwide Children's Hospital6
Completed
Not Applicable
Propranolol therapy for pediatric hemangioma and lymphangiomapediatric hemangioma and lymphangiomaJPRN-UMIN000005990Tohoku University Hospital
Recruiting
Not Applicable
Propranolol and Von Hippel-Lindau DiseaseHemangioblastoma of CNSVon Hippel-Lindau DiseaseNCT05424016Assistance Publique - Hôpitaux de Paris85
Completed
Not Applicable
Propranolol for infantile hemangiomasInfantile hemangiomasJPRN-UMIN000011944Plastic and Reconstructive Surgery, Keio university, School of medicine30